Bristol-Myers Squibb PE Ratio 2006-2018 | BMY

Current and historical price to earnings ratio for Bristol-Myers Squibb (BMY) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Bristol-Myers Squibb as of August 16, 2018 is 17.83.
Bristol-Myers Squibb Annual PE Ratio
Bristol-Myers Squibb Quarterly PE Ratio
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $98.497B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $349.931B 16.72
Pfizer (PFE) United States $245.020B 14.34
Novartis AG (NVS) Switzerland $189.637B 16.27
Merck (MRK) United States $181.642B 16.04
AbbVie (ABBV) United States $147.566B 14.42
Novo Nordisk (NVO) Denmark $116.361B 18.60
Eli Lilly (LLY) United States $110.975B 20.54
Sanofi (SNY) France $101.327B 12.82
GlaxoSmithKline (GSK) United Kingdom $100.338B 13.40
AstraZeneca (AZN) United Kingdom $97.390B 10.71